Table 2.
Hepatocyte growth factor (HGF) and Met expression in primary tumors of CRCs.
| cases | One Subgroup TxN0M1 versus TxN0M0 (9 matches) |
The other subgroup TxN1-2M1 versus TxN1-2M0 versus TxN0M0 (21 matches) |
Total matched groups TxN0-2M1versus TxN1-2M0versus TxN0M0(x≥1) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| total | SLM | PT | SLM | LN | PT | SLM | LN | PT | |
| cases | 81 | 9 | 9 | 21 | 21 | 21 | 30 | 21 | 30 |
| HGF expression in primary tumors | |||||||||
| Negative | 42 | 3 | 4 | 6 | 12 | 17 | 9 | 12 | 21 |
| (52%) | 33% | 44% | 29% | 57% | 81% | 30% | 57% | 70% | |
| Positive | 39 | 6 | 5 | 15 | 9 | 4 | 21 | 9 | 9 |
| (48%) | 67% | 56% | 71% | 43% | 19% | 70% | 43% | 30% | |
| P value | Mann-Whitney | Kruscal Wallis test | Kruscal Wallis test | ||||||
| Z=-0.470 | Chi-square=11.574 | Chi-square=9.808 | |||||||
| P=0.734 | P=0.003 | P=0.007 | |||||||
| Met expression in primary tumors of different groups | |||||||||
| Weak (Negative) |
21 | 1 | 3 | 2 | 3 | 12 | 3 | 3 | 15 |
| 26% | 11% | 33% | 10% | 14% | 57% | 10% | 14% | 50% | |
| Moderate (Positive) |
47 | 6 | 5 | 15 | 13 | 8 | 21 | 13 | 13 |
| 58% | 67% | 56% | 71% | 62% | 38% | 70% | 62% | 43% | |
| Strong (Positive) |
13 | 2 | 1 | 4 | 5 | 1 | 6 | 5 | 2 |
| 16% | 22% | 11% | 19% | 24% | 5% | 20% | 24% | 7% | |
| P value | Mann-Whitney | Kruscal Wallis test | Kruscal Wallis test | ||||||
| Z=-1.102 | Chi-square=14.430 | Chi-square=15.54 | |||||||
| P=0.436 | P=0.001 | P=0.004 | |||||||
SLM: primary colorectal cancer with synchronous liver metastasis; LN: primary colorectal cancer with regional metastasis; PT: primary colorectal cancer without any metastasis.